trending Market Intelligence /marketintelligence/en/news-insights/trending/V-IIEuqWyGkdmxUKcVBb1w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Oasmia Pharmaceutical to move veterinary assets to US

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Oasmia Pharmaceutical to move veterinary assets to US

Oasmia Pharmaceutical AB (publ) intends to move all of its veterinary assets to the U.S. for further development and commercialization efforts.

The assets include Paccal Vet and Doxophos Vet, the company's products within the field of chemotherapy for companion animals, which they own worldwide distribution rights to, except for Japan.

Oasmia aims to transition the products on a broader scale to a larger number of veterinary clinics. In line with this, Oasmia will transfer all the rights for the two key products to its subsidiary in the U.S to further facilitate strategic development and collaborations.

The company believes it can garner significant market share of the expanding U.S. veterinary industry by reducing the side effects and making its two key products more appealing to general practitioners.

Oasmia expects to implement the strategic changes during 2017.